San Diego, CA, United States of America

David Michael Soper

This inventor holds 2 USPTO granted patents and 4 published patent applications. Top assignee: Biolegend, Inc.. Active years: 2025-2026.

USPTO Granted Patents = 2 

% Patents Active = 50.0

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2025-2026

Loading Chart...
2 patents (USPTO):Explore Patents

Title: David Michael Soper: Innovator in Biomedical Research

Introduction

David Michael Soper is a prominent inventor based in San Diego, CA. He has made significant contributions to the field of biomedical research, particularly in the detection of specific biological activities. With a total of 2 patents, Soper's work has the potential to impact various medical applications.

Latest Patents

Soper's latest patents include "USES OF IL-40 AND METHODS FOR DETECTING IL-40 ACTIVITY" and "Methods for detecting meteorin-β activity." The latter patent focuses on innovative methods for detecting the activity of Meteorin-β and its modified versions. These advancements are crucial for understanding and diagnosing various health conditions.

Career Highlights

David Michael Soper is currently associated with BioLegend, Inc., a company known for its commitment to providing high-quality reagents for biomedical research. His work at BioLegend has allowed him to explore and develop cutting-edge technologies that enhance research capabilities in the life sciences.

Collaborations

Soper collaborates with talented individuals such as Gerardo Arrevillaga Boni and Marcela Hernandez Ruiz. Their combined expertise fosters an environment of innovation and discovery, contributing to the advancement of biomedical research.

Conclusion

David Michael Soper is a notable inventor whose work in biomedical research continues to pave the way for new diagnostic methods and treatments. His contributions are invaluable to the scientific community and hold promise for future advancements in healthcare.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…